
    
      The Phase 1 will consist of a dose escalation of ALX148 in combination with venetoclax and
      azacitidine to evaluate safety and tolerability, and to identify the recommended Phase 2 dose
      of ALX148 in combination with venetoclax and azacitidine. The Phase 2 will evaluate the
      efficacy of ALX148 in combination with venetoclax and azacitidine for patients with AML.
    
  